keyword
https://read.qxmd.com/read/38492039/multicenter-evaluation-of-an-automated-multiplex-rna-based-molecular-assay-for-detection-of-alk-ros1-ret-fusions-and-met-exon-14-skipping-in-nsclc
#21
JOURNAL ARTICLE
Melchior Linea, Hirschmann Astrid, Hofman Paul, Bontoux Christophe, Concha Angel, Mrabet-Dahbi Salima, Vannuffel Pascal, Watkin Emmanuel, Putzová Martina, Scarpino Stefania, Cayre Anne, Martin Paloma, Stoehr Robert, Hartmann Arndt
The current study assessed the performance of the fully automated RT-PCR-based Idylla™ GeneFusion Assay, which simultaneously covers the advanced non-small cell lung carcinoma (aNSCLC) actionable ALK, ROS1, RET, and MET exon 14 rearrangements, in a routine clinical setting involving 12 European clinical centers. The Idylla™ GeneFusion Assay detects fusions using fusion-specific as well as expression imbalance detection, the latter enabling detection of uncommon fusions not covered by fusion-specific assays...
March 16, 2024: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/38489861/real-world-outcomes-of-italian-patients-with-advanced-non-squamous-lung-cancer-treated-with-first-line-pembrolizumab-plus-platinum-pemetrexed
#22
JOURNAL ARTICLE
Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Giulio Cerea, Giulia Pasello, Elisa Roca, Lorenzo Belluomini, Fabiana Letizia Cecere, Annalisa Guida, Anna Manzo, Vincenzo Adamo, Francesca Rastelli, Alessandra Bulotta, Fabrizio Citarella, Luca Toschi, Federica Zoratto, Diego Luigi Cortinovis, Rossana Berardi, Alessandro Follador, Annamaria Carta, Andrea Camerini, Flavio Salerno, Rosa Rita Silva, Editta Baldini, Alessio Cortellini, Matteo Brighenti, Matteo Santoni, Francesco Malorgio, Caterina Caminiti, Marcello Tiseo
PURPOSE: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. METHODS: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs)...
March 11, 2024: European Journal of Cancer
https://read.qxmd.com/read/38488488/radiation-induced-effects-on-tgf-%C3%AE-and-pdgf-receptor-signaling-in-cancer-associated-fibroblasts
#23
JOURNAL ARTICLE
Nannan Yang, Turid Hellevik, Rodrigo Berzaghi, Inigo Martinez-Zubiaurre
BACKGROUND: Cancer-associated fibroblasts (CAFs) consist of heterogeneous connective tissue cells and are often constituting the most abundant cell type in the tumor stroma. Radiation effects on tumor stromal components like CAFs in the context of radiation treatment is not well-described. AIM: This study explores potential changes induced by ionizing radiation (IR) on platelet-derived growth factor (PDGF)/PDGFRs and transforming growth factor-beta (TGF-β)/TGFβRs signaling systems in CAFs...
March 2024: Cancer reports
https://read.qxmd.com/read/38484776/uncommon-tumors-of-the-lung-recently-described-and-rediscovered-tumors
#24
JOURNAL ARTICLE
Cesar A Moran
CONTEXT.—: The great majority of primary pulmonary neoplasms are represented by non-small cell carcinomas-adenocarcinoma and squamous cell carcinoma. In addition, there is another group of neoplasms such as those of neuroendocrine origin that also represent a meaningful subset of primary lung neoplasms. Basically, any other tumor that is not in these groups of tumors may represent an unusual lung neoplasm. OBJECTIVE.—: To highlight more recently described unusual tumoral entities that may represent a challenge in diagnosis and that require awareness of their existence...
March 15, 2024: Archives of Pathology & Laboratory Medicine
https://read.qxmd.com/read/38484586/recent-development-of-vegfr-small-molecule-inhibitors-as-anticancer-agents-a-patent-review-2021-2023
#25
REVIEW
Jing Zeng, Qichuan Deng, Zheng Chen, Shuang Yan, Qin Dong, Yuyu Zhang, Yuan Cui, Ling Li, Yuxin He, Jianyou Shi
VEGFR, a receptor tyrosine kinase inhibitor (TKI), is an important regulatory factor that promotes angiogenesis and vascular permeability. It plays a significant role in processes such as tumor angiogenesis, tumor cell invasion, and metastasis. VEGFR is mainly composed of three subtypes: VEGFR-1, VEGFR-2, and VEGFR-3. Among them, VEGFR-2 is the crucial signaling receptor for VEGF, which is involved in various pathological and physiological functions. At present, VEGFR-2 is closely related to a variety of cancers, such as non-small cell lung cancer (NSCLC), Hepatocellular carcinoma, Renal cell carcinoma, breast cancer, gastric cancer, glioma, etc...
March 9, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38482671/biphenotypic-lung-carcinoma-with-coexpression-of-ttf-1-and-%C3%AE-np63-p40-within-most-of-the-same-individual-cells-a-further-case-confirming-poor-prognosis-and-a-review-of-literature
#26
REVIEW
Alessandro Marando, Moreno Zagni, Mariachiara Negrelli, Emanuele Valtorta, Calogero Lauricella, Valentina Motta, Silvio Veronese, Giulio Cerea, Laura Giuseppina Giannetta, Gabriele Ciarlo, Diego Signorelli, Elio Gregory Pizzutilo, Emanuela Bonoldi, Giuseppe Pelosi
The WHO Classification of Tumors, Thoracic Tumors, 5th edition, has outlined the use of TTF-1 and ΔNP63/P40 to discriminate between adenocarcinoma and squamous cell carcinoma. In 2015, the first description of a rare non-small cell lung carcinoma featuring co-expression of glandular and squamous differentiation within most of the same individual tumor cells was reported on, with ultrastructural and molecular demonstration of such a biphenotypic differentiation. We herein describe an additional case of this rare tumor entity, which is confirmed to be an aggressive neoplasm despite potential targets of therapy...
February 2024: Pathologica
https://read.qxmd.com/read/38480835/clobetasol-propionate-a-nrf-2-inhibitor-sensitizes-human-lung-cancer-cells-to-radiation-induced-killing-via-mitochondrial-ros-dependent-ferroptosis
#27
JOURNAL ARTICLE
Archita Rai, Raghavendra S Patwardhan, Sundarraj Jayakumar, Pradnya Pachpatil, Dhruv Das, Girish Ch Panigrahi, Vikram Gota, Sejal Patwardhan, Santosh K Sandur
Combining radiotherapy with Nrf-2 inhibitor holds promise as a potential therapeutic strategy for radioresistant lung cancer. Here, the radiosensitizing efficacy of a synthetic glucocorticoid clobetasol propionate (CP) in A549 human lung cancer cells was evaluated. CP exhibited potent radiosensitization in lung cancer cells via inhibition of Nrf-2 pathway, leading to elevation of oxidative stress. Transcriptomic studies revealed significant modulation of pathways related to ferroptosis, fatty acid and glutathione metabolism...
March 13, 2024: Acta Pharmacologica Sinica
https://read.qxmd.com/read/38478955/non-small-cell-lung-carcinoma-with-focal-coexpression-of-thyroid-transcription-factor-1-and-%C3%AE-np63-p40-a-case-report
#28
Kazuhiro Terada, Toshi Menju, Horoshi Date, Hironori Haga, Akihiko Yoshizawa
Most lung carcinomas are subtyped by their morphologies; however, immunohistochemistry is usually performed when it is difficult to determine. The most reliable antibodies for distinguishing lung adenocarcinoma from squamous cell carcinoma are thyroid transcription factor-1 (TTF-1) and p40 (ΔNp63). In general, these markers are mutually exclusive in their expression of lung primary carcinoma; however, a few cases of non-small cell lung carcinoma (NSCLC) with coexpression of both markers have been reported...
March 13, 2024: Thoracic Cancer
https://read.qxmd.com/read/38476207/esophageal-squamous-cell-carcinoma-transformed-into-neuroendocrine-carcinoma-after-neoadjuvant-immunochemotherapy-a-case-report
#29
Gaojie Xin, Naicheng Song, Ke Jiang
Immunotherapy provides durable responses for locally advanced esophageal carcinoma clinical therapy in numerous patients. However, the mechanisms of resistance to immunotherapy have not been elucidated. The phenomenon of the histological transformation of non-small cell lung cancer to small cell lung cancer resulting in resistance to immune checkpoint inhibitors (ICIs) has been reported. It remains unclear whether ICIs or chemotherapy could cause a similar transformation from esophageal squamous cell carcinoma (ESCC) to esophageal neuroendocrine carcinoma (ENEC)...
April 2024: Oncology Letters
https://read.qxmd.com/read/38476010/aberrant-timp-1-production-in-tumor-associated-fibroblasts-drives-the-selective-benefits-of-nintedanib-in-lung-adenocarcinoma
#30
JOURNAL ARTICLE
Paula Duch, Natalia Díaz-Valdivia, Marta Gabasa, Rafael Ikemori, Marselina Arshakyan, Patricia Fernández-Nogueira, Alejandro Llorente, Cristina Teixido, Josep Ramírez, Javier Pereda, Lourdes Chuliá-Peris, José Marcelo Galbis, Frank Hilberg, Noemí Reguart, Derek C Radisky, Jordi Alcaraz
The fibrotic tumor microenvironment is a pivotal therapeutic target. Nintedanib, a clinically approved multikinase antifibrotic inhibitor, is effective against lung adenocarcinoma (ADC) but not squamous cell carcinoma (SCC). Previous studies have implicated the secretome of tumor-associated fibroblasts (TAFs) in the selective effects of nintedanib in ADC, but the driving factor(s) remained unidentified. Here we examined the role of tissue inhibitor of metalloproteinase-1 (TIMP-1), a tumor-promoting cytokine overproduced in ADC-TAFs...
March 12, 2024: Cancer Science
https://read.qxmd.com/read/38476004/high-efficiency-egfr-genotyping-using-cell-free-dna-in-bronchial-washing-fluid
#31
JOURNAL ARTICLE
Yoshihiko Murata, Yumi Nakajima, Yukio Sato, Nobuyuki Hizawa, Daichi Yamakawa, Daisuke Matsubara, Masayuki Noguchi, Yuko Minami
BACKGROUND: EGFR mutation testing is required for treatment of lung adenocarcinoma using epidermal growth factor receptor-tyrosine kinase inhibitor. However, the amounts of tumor tissue or tumor cells obtained by bronchoscopy are often insufficient. Bronchial washing fluid, obtained by lavage with saline after tumor biopsy or brushing, and the supernatant of bronchial washing fluid are thought to contain cell-free DNA that would be potentially applicable for EGFR testing. METHODS: From among patients with suspected adenocarcinoma or non-small cell lung carcinoma diagnosed from biopsy or surgical specimens at the University of Tsukuba Hospital between 2015 and 2019, cell-free DNAs from 80 specimens of supernatant of bronchial washing fluid (50 with EGFR mutation and 30 with wild type EGFR) and 8 blood serum samples were examined for EGFR mutation using droplet digital PCR...
March 12, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38473355/cost-effectiveness-of-treatment-optimisation-with-biomarkers-for-immunotherapy-in-solid-tumours-a-systematic-review
#32
REVIEW
Sara Mucherino, Valentina Lorenzoni, Isotta Triulzi, Marzia Del Re, Valentina Orlando, Annalisa Capuano, Romano Danesi, Giuseppe Turchetti, Enrica Menditto
This study investigated the health economic evaluations of predictive biomarker testing in solid tumours treated with immune checkpoint inhibitors (ICIs). Searching PubMed, EMBASE, and Web of Science from June 2010 to February 2022, 58 relevant articles were reviewed out of the 730 screened. The focus was predominantly on non-small cell lung cancer (NSCLC) (65%) and other solid tumours (40%). Among the NSCLC studies, 21 out of 35 demonstrated cost-effectiveness, notably for pembrolizumab as first-line treatment when preceded by PD-L1 assessment, cost-effective at a threshold of $100,000/QALY compared to the standard of care...
February 29, 2024: Cancers
https://read.qxmd.com/read/38473263/expanding-broad-molecular-reflex-testing-in-non-small-cell-lung-cancer-to-squamous-histology
#33
JOURNAL ARTICLE
Martin Zacharias, Selma Konjic, Nikolaus Kratochwill, Gudrun Absenger, Angelika Terbuch, Philipp J Jost, Robert Wurm, Jörg Lindenmann, Karl Kashofer, Franz Gollowitsch, Gregor Gorkiewicz, Luka Brcic
Due to the success story of biomarker-driven targeted therapy, most NSCLC guidelines agree that molecular reflex testing should be performed in all cases with non-squamous cell carcinoma (non-SCC). In contrast, testing recommendations for squamous cell carcinoma (SCC) vary considerably, specifically concerning the exclusion of patients of certain age or smoking status from molecular testing strategies. We performed a retrospective single-center study examining the value of molecular reflex testing in an unselected cohort of 316 consecutive lung SCC cases, tested by DNA- and RNA-based next-generation sequencing (NGS) at our academic institution between 2019 and 2023...
February 23, 2024: Cancers
https://read.qxmd.com/read/38469682/trem1-dap12-based-novel-multiple-chain-car-t-cells-targeting-dll3-show-robust-anti-tumour-efficacy-for-small-cell-lung-cancer
#34
JOURNAL ARTICLE
Fengqi Nie, Yuli Chen, Yanming Hu, Peng Huang, Xuefei Shi, Jingsheng Cai, Mantang Qiu, Enxiu Wang, Kaihua Lu, Ming Sun
Small cell lung cancer (SCLC), recognized as the most aggressive subtype of lung cancer, presents an extremely poor prognosis. Currently, patients with small cell lung cancer face a significant dearth of effective alternative treatment options once they experience recurrence and progression after first-line therapy. Despite the promising efficacy of immunotherapy, particularly immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and various other tumours, its impact on significantly enhancing the prognosis of SCLC patients remains elusive...
March 12, 2024: Immunology
https://read.qxmd.com/read/38469239/ret-gene-fusion-and-emergent-selpercatinib-resistance-in-a-calcitonin-rich-neuroendocrine-carcinoma-a-case-report
#35
Reza Pishdad, Peter B Illei, Christopher D Gocke, Douglas W Ball
Metastatic lung neuroendocrine carcinomas provide diagnostic challenges in identifying the cell of origin. High level calcitonin expression is not pathognomonic for medullary thyroid cancer. Tumor mutation analysis may provide essential clues regarding tissue origin and treatment targets. Oncogenic RET gene fusions have been identified in non-small cell lung cancer and non-medullary thyroid cancers, whereas RET point mutations are the key genetic finding in both inherited and sporadic MTC. Patients who receive radiation for the treatment of other cancers have an increased risk of developing a second malignancy, including a neuroendocrine carcinoma...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38469002/necrotizing-pneumonia-a-skeletal-muscle-lesion-and-a-fungating-duodenal-mass-an-atypical-presentation-of-rapidly-progressing-lung-adenocarcinoma
#36
Justin Ferkin, Brooke Williams, Phillip S Moore
Lung adenocarcinoma, the predominant subtype of non-small cell lung cancer, typically metastasizes to common sites such as the liver and adrenal glands. However, rare instances involve skeletal muscle metastasis. We present a case of a 45-year-old female with a medical history of hypertension, epilepsy, and fibromyalgia, who presented to the emergency department with hemoptysis and multifocal pain. Chest imaging revealed a cavitary lesion which appeared to be necrotizing pneumonia. Further investigations uncovered a fluid collection in the left thigh, which would be identified as poorly differentiated carcinoma...
February 2024: Curēus
https://read.qxmd.com/read/38468503/combination-tumor-treating-fields-treatment-for-patients-with-metastatic-non-small-cell-lung-cancer-a-cost-effectiveness-analysis
#37
JOURNAL ARTICLE
Kun Liu, Youwen Zhu, Hong Zhu, Manting Zeng
BACKGROUND: Tumor-treating field (TTFields) was a novel antitumor therapy that provided significant survival for previously treated metastatic non-small cell lung cancer (mNSCLC). The consistency of the cost of the new treatment regimen with its efficacy was the main objective of the study. METHODS: The primary parameters, derived from the Phase 3 LUNAR study, were collected to evaluate the cost and efficacy of TTFields plus standard-of-care (SOC) (immune checkpoint inhibitors [ICIs] and docetaxel [DTX]) or SOC in patients with mNSCLC by establishing a three-state Markov model over a 15-year time horizon...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38466508/gabpb1-plays-a-cancer-promoting-role-in-non-small-cell-lung-cancer
#38
JOURNAL ARTICLE
Tuo Wang, Cong Cao, Yu Fan, Jialing Xu, Tao Hua, Jie Ding, Zejie Liu, Beili Wang, Juanwen Lian
BACKGROUND: GABPB1, the gene that encodes two isoforms of the beta subunit of GABP, has been identified as an oncogene in multiple malignant tumors. However, the role and mode of action of GABPB1 in malignant tumors, especially in lung cancer, are not well understood and need further research. METHODS: Our research focused on examining the biological function of GABPB1 in NSCLC (Non-Small Cell Lung Cancer). We analysed tumor data from public databases to assess the expression of GABPB1 in NSCLC  and its correlation with patient prognosis and investigated GABPB1 expression and methylation patterns in relation to the tumor microenvironment...
March 11, 2024: Discover. Oncology
https://read.qxmd.com/read/38465177/nintedanib-in-combination-with-chemotherapy-in-the-treatment-of-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#39
REVIEW
Abdulhameed Alhadeethi, Sara Adel Awwad, Mohamed Abed, Ahmed Mostafa Amin, Menna M Aboelkhier, Mazen Negmeldin Aly Yassin, Maha H Morsi, Muataz Omar Kashbour
Lung cancer remains a major global health challenge, contributing to substantial morbidity and mortality rates. Nintedanib, a tyrosine kinase inhibitor, has demonstrated potential as a treatment for lung cancer. We aim to evaluate nintedanib's efficacy in treating patients with non-small cell lung cancer (NSCLC), depending on the available evidence. Our search for relevant articles was conducted on PubMed, Cochrane Library, Scopus, and Web of Science for randomized controlled trials (RCTs) that involved adult patients with NSCLC up to August 15, 2023...
February 2024: Curēus
https://read.qxmd.com/read/38464519/prognostic-impact-of-clinical-factors-for-immune-checkpoint-inhibitor-with-or-without-chemotherapy-in-older-patients-with-non-small-cell-lung-cancer-and-pd-l1-tps-%C3%A2-50
#40
JOURNAL ARTICLE
Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
INTRODUCTION: The proportion of older patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) has been increasing. Immune checkpoint inhibitor (ICI) monotherapy (MONO) and combination therapy of ICI and chemotherapy (COMBO) are standard treatments for patients with NSCLC and programmed cell death ligand-1 (PD-L1) tumor proportion scores (TPS) ≥ 50%. However, evidence from the clinical trials specifically for older patients is limited. Thus, it is unclear which older patients benefit more from COMBO than MONO...
2024: Frontiers in Immunology
keyword
keyword
117219
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.